DelveInsight launched a new report on Idiopathic Pulmonary Fibrosis Epidemiology Forecast, 2030.
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive disease characterized by the aberrant accumulation of fibrotic tissue in the lungs, associated with significant morbidity and poor prognosis. It is the most common form of fibrosing idiopathic interstitial pneumonia, is an inexorably progressive disease with a 5-year survival of ~20%.
DelveInsight’s ‘Idiopathic Pulmonary Fibrosis Epidemiology Forecast to 2030‘ report delivers an in-depth understanding of the disease, historical and forecasted Idiopathic Pulmonary Fibrosis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Some of the key highlights from the Idiopathic Pulmonary Fibrosis Epidemiology Report:
-
The total prevalent population of Idiopathic Pulmonary Fibrosis (IPF) in the 7MM is expected to rise to 284,823 by 2030, during the study period [2017–2030].
-
The epidemiological data, presented by the National Institute of Health (NIH), estimated that IPF has a prevalence of 13 to 20 per 100,000 people worldwide.
Visit for more @ Idiopathic Pulmonary Fibrosis Epidemiology Insights
Scope of the Idiopathic Pulmonary Fibrosis Epidemiology report:
-
The Idiopathic Pulmonary Fibrosis report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns
-
The Idiopathic Pulmonary Fibrosis Epidemiology Report and Model provide an overview of the risk factors and global trends of Idiopathic Pulmonary Fibrosis in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
-
The report provides insight into the historical and forecasted patient pool of Idiopathic Pulmonary Fibrosis in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
-
The report helps to recognize the growth opportunities in the 7MM concerning the patient population
-
The report assesses the disease risk and burden and highlights the unmet needs of Idiopathic Pulmonary Fibrosis
-
The report provides the segmentation of the Idiopathic Pulmonary Fibrosis epidemiology
Table of Contents:
1. Key Insights
2. Executive Summary of Idiopathic Pulmonary Fibrosis
3. Idiopathic Pulmonary Fibrosis Epidemiology Overview at a Glance
4. Idiopathic Pulmonary Fibrosis: Disease Background and Overview
5. Epidemiology and Patient Population
6. Case Reports
7. Country Wise-Epidemiology of Idiopathic Pulmonary Fibrosis
8. Appendix
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
Related Reports:
Idiopathic Pulmonary Fibrosis Market
DelveInsight’s ‘Idiopathic Pulmonary Fibrosis-Market Insights, Epidemiology, and Market Forecast—2030’ report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),
Idiopathic Pulmonary Fibrosis Pipeline
“Idiopathic Pulmonary Fibrosis Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Idiopathic Pulmonary Fibrosis market. A detailed picture of the Idiopathic Pulmonary Fibrosis pipeline landscape is provided, which includes the disease overview and Idiopathic Pulmonary Fibrosis treatment guidelines.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/